Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective
J. bras. nefrol; 38 (3), 2016
Abstract Introduction: Secondary hyperparathyroidism (SHPT) is a consequence of chronic kidney disease. The treatment at the Brazilian Unified Heath System (SUS) is performed with calcitriol, a drug which favors hypercalcemia and/or hyperphosphatemia, hindering the control of SHPT. Another option is par...
Conservadores de la Densidad Ósea/economía, Conservadores de la Densidad Ósea/uso terapéutico, Brasil, Calcitriol/economía, Calcitriol/uso terapéutico, Análisis Costo-Beneficio, Atención a la Salud, Ergocalciferoles/economía, Ergocalciferoles/uso terapéutico, Hiperparatiroidismo Secundario/tratamiento farmacológico, Hiperparatiroidismo Secundario/economía, Diálisis Renal